Sickle Cell Disease (SCD) Decision Aid
Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease
The purpose of this study is to gather decision making needs information from caregivers and patients with sickle cell disease (SCD) in order to develop a web-based decision aid tool. Study subjects will participate in interviews defining treatment decision making needs during which investigators will ask information about their SCD. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.
An additional group of participants will be asked to review the web-based Sickle Cell Decision Aid. Participants will be asked to describe thoughts about the site, including but not limited to ease of navigation, content and construction.
This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The purpose of this study is to understand patient, family and caregiver needs when making a decision about treatment for their sickle cell disease (SCD). Investigators are developing a decision aid tool that can help people understand SCD treatment options.
One group of subjects will participate in qualitative interviews defining treatment decision making needs during which investigators will ask information about their SCD. Investigators will also discuss treatment choices: hydroxyurea, chronic or monthly blood transfusions and bone marrow transplantation. Participants will be asked their thoughts about how to develop a web-based decision aid tool. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.
An additional group of subjects will review the web-based Sickle Cell Decision Aid. Participants will be asked to navigate the site. As the participant navigates the site, the study interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Using qualitative data collection methods, questions will be analyzed allowing for increased focus of questions based on common themes and issues identified during ongoing analysis.
This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-Individual diagnosed with sickle cell disease (SCD) or parent/legal guardian/caregiver of individual (of any age) diagnosed with SCD
Exclusion Criteria:
There are no exclusions to study participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Decisional Needs Assessment
Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
|
Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment.
Participants will be asked to describe what is important when making health care decisions.
Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed.
The interview will be audio recorded and will take 45 to 60 minutes to complete.
|
|
Outro: Beta Testing
Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
|
Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies.
As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction.
Testing may be performed in-person or via telephone.
Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient/Caregiver Knowledge of Treatment Risks
Prazo: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment risks will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Patient/Caregiver Knowledge of Treatment Benefits
Prazo: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment benefits will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Patient/Caregiver Treatment Expectations
Prazo: Up to 90 Minutes
|
Patient and caregiver treatment expectations will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Barriers to Understanding Treatment Options
Prazo: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment options will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB00076096
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Anemia falciforme
-
Xuzhou Central HospitalConcluídoInfarto Agudo do Miocárdio (IAM) | Principais Eventos Adversos Cardiovasculares | Red Blood Cell Distribution Width-to-albumin RatioChina
-
Kyowa Kirin, Inc.Ainda não está recrutandoT-Cell NHL (PTCL ou CTCL)Estados Unidos, Itália, Espanha
-
Taichung Veterans General HospitalConcluídoCardiotoxicidade | Carcinoma de Pulmão de Células não Pequenas (Termo MeSH: Carcinoma, Non-Small-Cell Lung) | Efeitos Secundários e Reações Adversas Relacionadas com Medicamentos (Termo MeSH) | Inibidor da Tirosina Quinase do EgfrTaiwan
-
Fondazione del Piemonte per l'OncologiaRecrutamentoCâncer de mama | Cancro do ovário | Câncer colorretal | Melanoma (câncer de pele) | Carcinoma de Pulmão de Células não Pequenas (Termo MeSH: Carcinoma, Non-Small-Cell Lung)Itália
-
Novartis PharmaceuticalsRescindidoMelanoma | Avançado EGFR mutante non Small Cell LungCancer (NSCLC) | KRAS G12-MUTANT NSCLC | Câncer de células escamosas esofágicas (SCC) | Cabeça/pescoço SCC | Tumores estromais gastrointestinais avançados (GIST) | NRAS/Braft WT avançado melanoma cutâneoEstados Unidos, Taiwan, Holanda, Canadá, Espanha, Cingapura, Itália, Japão, Coréia do Sul
Ensaios clínicos em Qualitative Interviews Decisional Needs Assessment
-
Mahidol UniversityConcluídoFerramenta de triagem para depressão em pacientes com dor oncológicaTailândia